<DOC>
	<DOCNO>NCT00554398</DOCNO>
	<brief_summary>An intensification HIV-1 integrase inhibitor Raltegravir ( RAL ) stable HAART regimen persistent HIV-1 viral suppression could increase slope decay HIV-1 latent reservoir .</brief_summary>
	<brief_title>Impact MK-0518 ( Raltegravir ) Intensification HIV-1 Viral Latency Patients With Previous Complete Viral Suppression</brief_title>
	<detailed_description>While highly active antiretroviral therapy ( HAART ) reduce plasma HIV-1 level limit detection standard assay , replication-competent virus persist stable , latent reservoir rest CD4+ T cell . So , rapid resumption plasma viremia therapy interrupt . In addition cellular reservoir , pharmacologically privilege area central nervous system genital tract might act additional source residual virus patient undetectable level plasma HIV-1 RNA . There great current interest strategy deplete eliminate reservoir . The antiviral potency current regimen emerge important determinant complete viral control . In certain patient , latent reservoir decay hasten treatment intensification . An intensification HIV-1 integrase inhibitor Raltegravir ( RAL ) stable HAART regimen persistent HIV-1 viral suppression could increase slope decay HIV-1 latent reservoir . This could provide insight area , decrease size latent reservoir , translate clinical benefit patient simplify maintenance monotherapy RAL HIV-1 rebound kinetics slope program treatment interruption .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIV1 infect adult ( +18 year old ) . 2 . Complete virological suppression ( &lt; 50 copies/mL ) += 12 month , include least 3 time last year . 3 . Patients HAART regimen include PI NNRTI least two nucleotide inhibitor . 4 . Voluntary write informed consent . 1 . Pregnancy , fertile woman willing pregnant . 2 . Active substance abuse major psychiatric disease . 3 . Presence drugrelated mutation polymorphism mutation associate MK0518 resistance prior first HAART ( genotype available ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>MK-0518</keyword>
	<keyword>Treatment intensification</keyword>
	<keyword>HIV-1 latency</keyword>
	<keyword>HIV eradication</keyword>
	<keyword>treatment experience</keyword>
</DOC>